Showing results (1-10 of 18) with videos related to
Sort By:
Pageof 2
Expert Opinion on Pharmacotherapy|May 5, 2001
The current status of antihypertensive treatments: into the new millenniumT C Hardman, M W LunnonJournal of Hypertension|June 1, 1996
Controversies surrounding erythrocyte sodium-lithium countertransportT C Hardman, A F LantThe Journal of Membrane Biology|January 22, 1998
Characterization of the erythrocyte sodium-lithium countertransporter: limitations and assumptions of traditional and kinetic methodologiesT C Hardman, T Thomas, A F LantInternational Journal of Clinical Practice|February 21, 2012
New lipid-lowering drugs: an updateA S Wierzbicki, T C Hardman, A ViljoenJournal of Human Hypertension|July 1, 1995
Relation of sodium-lithium countertransport activity to markers of cardiovascular risk in normotensive subjectsT C Hardman, S W Dubrey, S Soni, et al.Metabolism: Clinical and Experimental|October 1, 1996
Kinetic behavior of the erythrocyte sodium-lithium countertransporter in nonnephropathic diabetic twinsT C Hardman, S W Dubrey, R D Leslie, et al.Diabetes Care|January 1, 1996
Erythrocyte sodium-lithium countertransport activity in non-nephropathic diabetic twinsT C Hardman, S W Dubrey, R D Leslie, et al.Journal of Human Hypertension|March 3, 1998
Kinetic characteristics of the erythrocyte sodium-lithium countertransporter in black normotensive subjects compared with three other ethnic groupsT C Hardman, P Croft, Z Morrish, et al.American Journal of Hypertension|February 1, 1996
Kinetic characteristics of the erythrocyte sodium-lithium countertransporter in subjects with coronary artery diseaseT C Hardman, R Barlow, S W Dubrey, et al.Journal of Human Hypertension|June 1, 1996
Angiotensin-converting enzyme (ACE) gene polymorphism and the erythrocyte sodium-lithium countertransporter (SLC) phenotype in hypertensionT C Hardman, A S Wierzbicki, P Croft, et al.Pageof 2